Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 95.8%

Neg 95.8% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.